Joyce Qian

Joyce Qian

Auto-generated profile, based on publicly available information

Joyce Qian

Kyowa Kirin, Inc., Princeton, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
MTMae Thamer
Mae Thamer
JKJames S. Kaufman
James S. Kaufman
YZYi Zhang
Yi Zhang
QZQian Zhang
Qian Zhang
DCDennis J. Cotter
Dennis J. Cotter
HBHeejung Bang
Heejung Bang

9 July 2020 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
JQJoyce Z. Qian
Joyce Z. Qian
MMMara McAdams-DeMarco
Mara McAdams-DeMarco
DNDerek K. Ng
Derek K. Ng
BLBryan Lau
Bryan Lau

10 December 2019 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
JQJoyce Z. Qian
Joyce Z. Qian
MMMara A. McAdams-DeMarco
Mara A. McAdams-DeMarco
DNDerek Ng
Derek Ng
BLBryan Lau
Bryan Lau
Background: Choice of vascular access for older hemodialysis patients presents a special challenge since the rate of arteriovenous fistula (AVF) primary failure is high. The Lok’s risk equation predicting AVF primary failure has achieved good prediction accuracy and holds great potential for clinical use, but it has not been validated in the United States older hemodialysis patients. Methods: We assembled a validation data set of 14,892 patients aged 67 years and older who initiated hemodialysis with a central venous catheter between July 1, 2010, and June 30, 2012, and had a subsequent, incident AVF placement from the United States Renal Data System. We examined the external validity of Lok’s model by applying it to this validation data set. The discriminatory accuracy and calibration were evaluated by the concordance index (C-statistics) and calibration plot, respectively. Results: The observed frequency of AVF primary failure varied from 0.45 to 0.53 in hemodialysis patients in the validation data set. The predicted probabilities of AVF primary failure calculated by using the Lok’s risk equation ranged from 0.08 to 0.61, and 77.8, 40.5, and 51.7% of patients were categorized as having high, intermediate, and low risk of AVF primary failure, respectively. The C-statistics of the Lok’s risk equation in the validation data set was 0.53 (95% CI 0.52–0.54). The predicted probabilities of AVF primary failure corresponded poorly with the observed proportions in the calibration plot. Conclusions: When externally applied to a cohort of U.S. older hemodialysis patients, the Lok’s risk equation exhibited poor discrimination and calibration accuracy. It is invalid to use it to predict AVF primary failure. A more complex model with strong predictors is expected to better serve clinical determination for AVF placement in this population.

1 January 2025 in Clinical Neuropharmacology
Verified
Journal Article
Open access
YTYasar Torres-Yaghi
Yasar Torres-Yaghi
JQJoyce Qian
Joyce Qian
HCHannah Cummings
Hannah Cummings
HSHiroo Bs Shimoda
Hiroo Bs Shimoda
SISatoru Ito
Satoru Ito
FPFernando Pagan
Fernando Pagan
Introduction: Adjunctive therapies to treat OFF episodes resulting from long-term levodopa treatment in Parkinson disease (PD) are hampered by safety and tolerability issues. Istradefylline offers an alternative mechanism (adenosine A2A receptor antagonist) and therefore potentially improved tolerability. Methods: A systematic review of PD adjuncts published in 2011 was updated to include randomized controlled trials published from January 1, 2010–April 15, 2019. Pairwise meta-analyses were updated, and Bucher indirect comparisons were used to generate estimates of relative safety, presented as odds ratio (OR) and 95% confidence interval (CI) for comparators versus istradefylline. Results: Fifty-seven randomized controlled trials involving 11,517 patients were included in the meta-analysis. Relative to istradefylline, dopamine agonists and catechol-O-methyl transferase (COMT) inhibitors had statistically significant higher odds of dyskinesia and somnolence. Monoamine oxidase-B inhibitors had significantly higher odds of hypotension. Amantadine extended-release (ER) had statistically significant higher odds of hallucination, orthostatic hypotension, insomnia, and withdrawals due to adverse events. All interventions combined had significantly higher odds of dyskinesia versus istradefylline 20 mg and somnolence versus istradefylline 40 mg. Considering overall incidence of adverse events, COMT inhibitors and amantadine ER had statistically significant higher odds versus both istradefylline doses (COMT versus istradefylline 40 mg, OR: 1.33; 95% CI: 1.03, 1.75; versus istradefylline 20 mg, OR: 1.32; 95% CI: 1.01, 1.72; amantadine ER versus istradefylline 40 mg, OR: 3.45; 95% CI: 1.85, 6.25; versus istradefylline 20 mg, OR: 3.33; 95% CI: 1.82, 6.25). Conclusion: Istradefylline was associated with a generally favorable safety profile relative to other adjunct medications in this study.

11 March 2020 in Seminars in Dialysis
Verified
Journal Article
Closed access
PDF file
JQJoyce Qian
Joyce Qian
MMMara McAdams‐DeMarco
Mara McAdams‐DeMarco
DNDerek Ng
Derek Ng
BLBryan Lau
Bryan Lau

17 February 2025 in Clinical Parkinsonism & Related Disorders
Verified
Journal Article
Open access
SBSagari Betté
Sagari Betté
JQJoyce Qian
Joyce Qian
HCHannah Cummings
Hannah Cummings
HSHiroo Shimoda
Hiroo Shimoda
KSKatsumi Shinoda
Katsumi Shinoda
DTDaniel Truong
Daniel Truong
Istradefylline offers a novel mechanism (adenosine A2A receptor antagonism) to treat OFF episodes in Parkinson's disease (PD). It may potentially offer improved tolerability versus other adjuncts, but comparative safety data are lacking. A systematic review and Bayesian network meta-analysis (NMA) incorporating RCTs of PD adjuncts until January 10, 2024, was conducted to estimate relative safety. Inconsistency was assessed and heterogeneity evaluated by global I2-statistic and between-study heterogeneity. Incidences of safety outcomes were summarized from RWE identified according to the same criteria. 100 RCTs and 55 RWE publications were identified; 76 RCTs were included in NMAs. Istradefylline demonstrated lower odds of serious AEs (odds ratio [OR] = 0.56; 95 % CrI: 0.32, 0.99), treatment-emergent AEs (0.43; 0.25, 0.73), treatment-related AEs (0.33; 0.19, 0.56), hallucinations (0.25; 0.06, 0.97), and withdrawal due to AEs (0.37; 0.19, 0.68) versus amantadine. Istradefylline showed lower odds of dyskinesia (0.63; 0.41, 0.99) and hypotension (0.19; 0.03, 0.82) versus catechol-O-methyl transferase inhibitors (COMTi), lower odds of nausea (0.58; 0.33, 0.99) versus dopamine agonists (DA), and lower odds of hypotension (0.09; 0.01, 0.52) versus monoamine oxidase-B inhibitors (MAO-Bi). Sensitivity analysis of RCTs published since 2000 found a reduction in odds of dyskinesia and hallucinations for istradefylline versus DA. RWE were heterogeneous but demonstrated lower incidence of certain AEs with istradefylline, specifically dyskinesia (versus MAO-Bi), somnolence (versus DA and COMTi), peripheral edema and hallucinations (versus amantadine), and nausea (versus all comparators). Istradefylline exhibits a favorable safety profile versus other PD adjuncts, as demonstrated by RCTs and RWE.